Vancomycin (as HCl) 500mg/vial, 1g/vial; lyophilized pwd for IV infusion after reconstitution and dilution. Not for prophylaxis of endophthalmitis. Renal insufficiency. Monitor hearing, blood, renal ...

The US Food and Drug Administration (FDA) is issuing a compounding risk warning against intraocular injections of vancomycin either alone or in combination with other drugs, in light of a new case of ...

Ready-to-infuse sepsis therapy marks new advancement in time-critical treatment LONDON, July 2, 2025 /PRNewswire/ -- Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, today ...

Please provide your email address to receive an email when new articles are posted on . The FDA is warning against the use of prophylactic intraocular vancomycin formulations during cataract surgery ...

Please provide your email address to receive an email when new articles are posted on . Intraosseous vancomycin levels were minimally detected at the end of the procedure vs. IV vancomycin levels.

(RTTNews) - Hospira, Inc., affiliated to Pfizer Inc., is recalling one lot of Vancomycin Hydrochloride Injection, USP 1.5g/vial, citing the presence of visible glass particulates, the U.S. Food and ...

Vancomycin (Vanacin CP 500mg Injection) is a glycopeptide antibiotic, prescribed for serious bacterial infections, endocarditis and surgical prophylaxis in major procedures. It kills sensitive ...

(RTTNews) - Glenmark Pharmaceuticals Inc., USA, affiliated to India-based Glenmark Pharmaceuticals Ltd., announced Tuesday the launch of Vancomycin Hydrochloride for Injection USP in single-dose vials ...

TYZAVAN ™ is a glycopeptide antibacterial indicated for the treatment of the following infections in adult and pediatric patients (1 month and older) for whom appropriate dosing with this formulation ...

Glenmark Pharmaceuticals Ltd. (BSE: 532296) (NSE: GLENMARK) is a research–led, global pharmaceutical company, having a presence across Branded, Generics, and OTC segments; with a focus on therapeutic ...

LONDON, July 2, 2025 /PRNewswire/ -- Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, today announced the approval of a novel formulation of the first-of-its-kind, ready-to ...